vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and TRICO BANCSHARES (TCBK). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $109.4M, roughly 1.6× TRICO BANCSHARES ). TRICO BANCSHARES runs the higher net margin — 251.6% vs 1.6%, a 250.0% gap on every dollar of revenue. On growth, TRICO BANCSHARES posted the faster year-over-year revenue change (9.0% vs 5.0%). Over the past eight quarters, TRICO BANCSHARES 's revenue compounded faster (5.4% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.
PCRX vs TCBK — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $109.4M |
| Net Profit | $2.9M | $33.6M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | 42.6% |
| Net Margin | 1.6% | 251.6% |
| Revenue YoY | 5.0% | 9.0% |
| Net Profit YoY | — | 15.8% |
| EPS (diluted) | $0.07 | $1.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $109.4M | ||
| Q3 25 | $179.5M | $107.6M | ||
| Q2 25 | $181.1M | $103.6M | ||
| Q1 25 | $168.9M | $98.6M | ||
| Q4 24 | $187.3M | $100.4M | ||
| Q3 24 | $168.6M | $99.1M | ||
| Q2 24 | $178.0M | $97.9M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $33.6M | ||
| Q3 25 | $5.4M | $34.0M | ||
| Q2 25 | $-4.8M | $27.5M | ||
| Q1 25 | $4.8M | $26.4M | ||
| Q4 24 | — | $29.0M | ||
| Q3 24 | $-143.5M | $29.1M | ||
| Q2 24 | $18.9M | $29.0M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 42.6% | ||
| Q3 25 | 3.5% | 43.2% | ||
| Q2 25 | 4.7% | 36.5% | ||
| Q1 25 | 1.2% | 35.8% | ||
| Q4 24 | 13.2% | 38.7% | ||
| Q3 24 | -82.8% | 39.8% | ||
| Q2 24 | 15.9% | 40.0% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 251.6% | ||
| Q3 25 | 3.0% | 31.6% | ||
| Q2 25 | -2.7% | 26.6% | ||
| Q1 25 | 2.8% | 26.7% | ||
| Q4 24 | — | 221.4% | ||
| Q3 24 | -85.1% | 29.3% | ||
| Q2 24 | 10.6% | 29.7% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $1.02 | ||
| Q3 25 | $0.12 | $1.04 | ||
| Q2 25 | $-0.11 | $0.84 | ||
| Q1 25 | $0.10 | $0.80 | ||
| Q4 24 | $0.38 | $0.88 | ||
| Q3 24 | $-3.11 | $0.88 | ||
| Q2 24 | $0.39 | $0.87 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $157.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $1.3B |
| Total Assets | $1.2B | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $157.0M | ||
| Q3 25 | $246.3M | $298.8M | ||
| Q2 25 | $445.9M | $314.3M | ||
| Q1 25 | $493.6M | $308.3M | ||
| Q4 24 | $484.6M | $145.0M | ||
| Q3 24 | $453.8M | $320.1M | ||
| Q2 24 | $404.2M | $206.6M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $1.3B | ||
| Q3 25 | $727.2M | $1.3B | ||
| Q2 25 | $757.8M | $1.3B | ||
| Q1 25 | $798.5M | $1.3B | ||
| Q4 24 | $778.3M | $1.2B | ||
| Q3 24 | $749.6M | $1.2B | ||
| Q2 24 | $879.3M | $1.2B |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $9.8B | ||
| Q3 25 | $1.3B | $9.9B | ||
| Q2 25 | $1.5B | $9.9B | ||
| Q1 25 | $1.6B | $9.8B | ||
| Q4 24 | $1.6B | $9.7B | ||
| Q3 24 | $1.5B | $9.8B | ||
| Q2 24 | $1.6B | $9.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $133.3M |
| Free Cash FlowOCF − Capex | — | $127.9M |
| FCF MarginFCF / Revenue | — | 116.9% |
| Capex IntensityCapex / Revenue | — | 4.9% |
| Cash ConversionOCF / Net Profit | — | 3.96× |
| TTM Free Cash FlowTrailing 4 quarters | — | $222.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $133.3M | ||
| Q3 25 | $60.8M | $45.1M | ||
| Q2 25 | $12.0M | $29.2M | ||
| Q1 25 | $35.5M | $24.5M | ||
| Q4 24 | $33.1M | $109.7M | ||
| Q3 24 | $53.9M | $28.6M | ||
| Q2 24 | $53.2M | $31.8M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $127.9M | ||
| Q3 25 | $57.0M | $43.2M | ||
| Q2 25 | $9.3M | $28.2M | ||
| Q1 25 | $26.9M | $22.8M | ||
| Q4 24 | $31.0M | $105.2M | ||
| Q3 24 | $49.8M | $27.3M | ||
| Q2 24 | $51.6M | $30.8M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 116.9% | ||
| Q3 25 | 31.7% | 40.2% | ||
| Q2 25 | 5.1% | 27.2% | ||
| Q1 25 | 15.9% | 23.1% | ||
| Q4 24 | 16.6% | 104.8% | ||
| Q3 24 | 29.6% | 27.6% | ||
| Q2 24 | 29.0% | 31.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 4.9% | ||
| Q3 25 | 2.2% | 1.7% | ||
| Q2 25 | 1.5% | 1.0% | ||
| Q1 25 | 5.1% | 1.7% | ||
| Q4 24 | 1.1% | 4.5% | ||
| Q3 24 | 2.4% | 1.3% | ||
| Q2 24 | 0.9% | 1.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.96× | ||
| Q3 25 | 11.20× | 1.33× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | 7.37× | 0.93× | ||
| Q4 24 | — | 3.78× | ||
| Q3 24 | — | 0.98× | ||
| Q2 24 | 2.82× | 1.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
TCBK
Segment breakdown not available.
